Submitted by Anonymous (not verified) on 30 November 2023 - 16:39
Human medicines European public assessment report (EPAR): Praluent, alirocumab, Dyslipidemias, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Praluent, alirocumab, Dyslipidemias, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised